ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

GENSCI122

A development code. Also written as “GenSci122 tablet 50mg” and “GenSci122 tablet 250mg”.

Its studies are led by Changchun GeneScience Pharmaceutical.

Furthest: phase 1, since Jan 2, 20251 company-led study, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Changchun GeneScience Pharmaceutical10 open or runningphase 1since Jan 2, 2025Jan 2, 2025none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 2, 2025First study: phase 1 study in Advanced Solid TumorFirst studyNCT06772415 · 163 enrolled · China
  2. Nov 17, 2026Phase 1 study terminatedStudy stoppedNCT06772415 · “The sponsor adjusted its research and development strategy”

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06772415Advanced Solid Tumor · China1TerminatedOct 22, 2026163

How it is read

Names in the registry

  • “GenSci122 tablet 50mg”, 1 entry
  • “GenSci122 tablet 250mg”, 1 entry

Codes read as this program: GENSCI122.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.